Adverum Biotechnologies Inc
NASDAQ:ADVM
Adverum Biotechnologies Inc
Revenue
Adverum Biotechnologies Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Adverum Biotechnologies Inc
NASDAQ:ADVM
|
Revenue
$3.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
17%
|
CAGR 10-Years
22%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
See Also
What is Adverum Biotechnologies Inc's Revenue?
Revenue
3.6m
USD
Based on the financial report for Dec 31, 2023, Adverum Biotechnologies Inc's Revenue amounts to 3.6m USD.
What is Adverum Biotechnologies Inc's Revenue growth rate?
Revenue CAGR 10Y
22%